JP2014510078A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014510078A5 JP2014510078A5 JP2013557904A JP2013557904A JP2014510078A5 JP 2014510078 A5 JP2014510078 A5 JP 2014510078A5 JP 2013557904 A JP2013557904 A JP 2013557904A JP 2013557904 A JP2013557904 A JP 2013557904A JP 2014510078 A5 JP2014510078 A5 JP 2014510078A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- cancer
- lymphoma
- cell
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 37
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 14
- 206010028980 Neoplasm Diseases 0.000 claims 13
- 201000011510 cancer Diseases 0.000 claims 11
- 210000003719 b-lymphocyte Anatomy 0.000 claims 10
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 10
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 9
- 230000014509 gene expression Effects 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- 239000012453 solvate Substances 0.000 claims 7
- 210000004027 cell Anatomy 0.000 claims 6
- RSNPAKAFCAAMBH-UHFFFAOYSA-N 3-(5-amino-2-methyl-4-oxoquinazolin-3-yl)piperidine-2,6-dione Chemical compound CC1=NC2=CC=CC(N)=C2C(=O)N1C1CCC(=O)NC1=O RSNPAKAFCAAMBH-UHFFFAOYSA-N 0.000 claims 5
- 206010060862 Prostate cancer Diseases 0.000 claims 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 5
- 101001011441 Homo sapiens Interferon regulatory factor 4 Proteins 0.000 claims 4
- 102100030126 Interferon regulatory factor 4 Human genes 0.000 claims 4
- 239000012472 biological sample Substances 0.000 claims 4
- 238000001574 biopsy Methods 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 206010009944 Colon cancer Diseases 0.000 claims 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 3
- 206010039491 Sarcoma Diseases 0.000 claims 3
- 239000000090 biomarker Substances 0.000 claims 3
- 208000005017 glioblastoma Diseases 0.000 claims 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 claims 2
- 102100028122 Forkhead box protein P1 Human genes 0.000 claims 2
- 208000017604 Hodgkin disease Diseases 0.000 claims 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 2
- 101001059893 Homo sapiens Forkhead box protein P1 Proteins 0.000 claims 2
- 101001131670 Homo sapiens PWWP domain-containing DNA repair factor 3A Proteins 0.000 claims 2
- 101000825182 Homo sapiens Transcription factor Spi-B Proteins 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 108010057466 NF-kappa B Proteins 0.000 claims 2
- 102000003945 NF-kappa B Human genes 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 2
- 239000003098 androgen Substances 0.000 claims 2
- 210000001185 bone marrow Anatomy 0.000 claims 2
- 238000012512 characterization method Methods 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 2
- 210000001165 lymph node Anatomy 0.000 claims 2
- 210000005259 peripheral blood Anatomy 0.000 claims 2
- 239000011886 peripheral blood Substances 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 239000000523 sample Substances 0.000 claims 2
- 208000010721 smoldering plasma cell myeloma Diseases 0.000 claims 2
- 210000004881 tumor cell Anatomy 0.000 claims 2
- BVJRNKXVSYLNFD-UHFFFAOYSA-N 3-(5-amino-2-methyl-4-oxoquinazolin-3-yl)piperidine-2,6-dione;hydrochloride Chemical compound Cl.CC1=NC2=CC=CC(N)=C2C(=O)N1C1CCC(=O)NC1=O BVJRNKXVSYLNFD-UHFFFAOYSA-N 0.000 claims 1
- -1 5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl Chemical group 0.000 claims 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 206010073128 Anaplastic oligodendroglioma Diseases 0.000 claims 1
- 206010003571 Astrocytoma Diseases 0.000 claims 1
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 206010006143 Brain stem glioma Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 102100024965 Caspase recruitment domain-containing protein 11 Human genes 0.000 claims 1
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 claims 1
- 206010058314 Dysplasia Diseases 0.000 claims 1
- 201000001342 Fallopian tube cancer Diseases 0.000 claims 1
- 208000013452 Fallopian tube neoplasm Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 206010016935 Follicular thyroid cancer Diseases 0.000 claims 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 101100219559 Homo sapiens CARD11 gene Proteins 0.000 claims 1
- 101000761179 Homo sapiens Caspase recruitment domain-containing protein 11 Proteins 0.000 claims 1
- 206010062904 Hormone-refractory prostate cancer Diseases 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 201000005099 Langerhans cell histiocytosis Diseases 0.000 claims 1
- 208000018142 Leiomyosarcoma Diseases 0.000 claims 1
- BGRDGMRNKXEXQD-UHFFFAOYSA-N Maleic hydrazide Chemical compound OC1=CC=C(O)N=N1 BGRDGMRNKXEXQD-UHFFFAOYSA-N 0.000 claims 1
- 208000009018 Medullary thyroid cancer Diseases 0.000 claims 1
- 206010059282 Metastases to central nervous system Diseases 0.000 claims 1
- 101000687343 Mus musculus PR domain zinc finger protein 1 Proteins 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010052399 Neuroendocrine tumour Diseases 0.000 claims 1
- 201000010133 Oligodendroglioma Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010033701 Papillary thyroid cancer Diseases 0.000 claims 1
- 229940123263 Phosphodiesterase 3 inhibitor Drugs 0.000 claims 1
- 229940123304 Phosphodiesterase 7 inhibitor Drugs 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 108010009975 Positive Regulatory Domain I-Binding Factor 1 Proteins 0.000 claims 1
- 102000009844 Positive Regulatory Domain I-Binding Factor 1 Human genes 0.000 claims 1
- 206010038019 Rectal adenocarcinoma Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000004346 Smoldering Multiple Myeloma Diseases 0.000 claims 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims 1
- 102100022281 Transcription factor Spi-B Human genes 0.000 claims 1
- 208000037280 Trisomy Diseases 0.000 claims 1
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 claims 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 150000003838 adenosines Chemical class 0.000 claims 1
- 229940100198 alkylating agent Drugs 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 206010002022 amyloidosis Diseases 0.000 claims 1
- 206010002224 anaplastic astrocytoma Diseases 0.000 claims 1
- 229960002707 bendamustine Drugs 0.000 claims 1
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 229960004630 chlorambucil Drugs 0.000 claims 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims 1
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 claims 1
- 238000011443 conventional therapy Methods 0.000 claims 1
- 239000013078 crystal Substances 0.000 claims 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 201000003444 follicular lymphoma Diseases 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 claims 1
- 208000013210 hematogenous Diseases 0.000 claims 1
- 210000000777 hematopoietic system Anatomy 0.000 claims 1
- 208000029824 high grade glioma Diseases 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 229940043355 kinase inhibitor Drugs 0.000 claims 1
- 201000010260 leiomyoma Diseases 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 201000011614 malignant glioma Diseases 0.000 claims 1
- 208000006178 malignant mesothelioma Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 206010027191 meningioma Diseases 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 208000010658 metastatic prostate carcinoma Diseases 0.000 claims 1
- 201000005962 mycosis fungoides Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 208000016065 neuroendocrine neoplasm Diseases 0.000 claims 1
- 201000011519 neuroendocrine tumor Diseases 0.000 claims 1
- 230000000683 nonmetastatic effect Effects 0.000 claims 1
- 230000002018 overexpression Effects 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 201000010198 papillary carcinoma Diseases 0.000 claims 1
- 201000002628 peritoneum cancer Diseases 0.000 claims 1
- 210000004786 perivascular cell Anatomy 0.000 claims 1
- 239000002570 phosphodiesterase III inhibitor Substances 0.000 claims 1
- 239000002606 phosphodiesterase VII inhibitor Substances 0.000 claims 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
- KNCYXPMJDCCGSJ-UHFFFAOYSA-N piperidine-2,6-dione Chemical compound O=C1CCCC(=O)N1 KNCYXPMJDCCGSJ-UHFFFAOYSA-N 0.000 claims 1
- 238000010837 poor prognosis Methods 0.000 claims 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 201000001281 rectum adenocarcinoma Diseases 0.000 claims 1
- 229960004641 rituximab Drugs 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 claims 1
- 201000009295 smoldering myeloma Diseases 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 208000030901 thyroid gland follicular carcinoma Diseases 0.000 claims 1
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 claims 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 1
- 229960004528 vincristine Drugs 0.000 claims 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161451995P | 2011-03-11 | 2011-03-11 | |
| US61/451,995 | 2011-03-11 | ||
| US201161480272P | 2011-04-28 | 2011-04-28 | |
| US61/480,272 | 2011-04-28 | ||
| PCT/US2012/028498 WO2012125459A1 (en) | 2011-03-11 | 2012-03-09 | Methods of treating cancer using 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017009923A Division JP6348192B2 (ja) | 2011-03-11 | 2017-01-24 | ３−（５−アミノ−２−メチル−４−オキソ−４ｈ−キナゾリン−３−イル）−ピペリジン−２，６−ジオンを用いる癌の治療方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014510078A JP2014510078A (ja) | 2014-04-24 |
| JP2014510078A5 true JP2014510078A5 (enExample) | 2015-04-23 |
Family
ID=45876915
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013557904A Withdrawn JP2014510078A (ja) | 2011-03-11 | 2012-03-09 | ３−（５−アミノ−２−メチル−４−オキソ−４ｈ−キナゾリン−３−イル）−ピペリジン−２，６−ジオンを用いる癌の治療方法 |
| JP2013557916A Expired - Fee Related JP6118273B2 (ja) | 2011-03-11 | 2012-03-09 | 免疫関連疾患及び炎症性疾患の治療における３−（５−アミノ−２−メチル−４−オキソキナゾリン−３（４ｈ）−イル）ピペリジン−２，６−ジオンの使用 |
| JP2016248598A Pending JP2017081959A (ja) | 2011-03-11 | 2016-12-22 | 免疫関連疾患及び炎症性疾患の治療における３−（５−アミノ−２−メチル−４−オキソキナゾリン−３（４ｈ）−イル）ピペリジン−２，６−ジオンの使用 |
| JP2017009923A Expired - Fee Related JP6348192B2 (ja) | 2011-03-11 | 2017-01-24 | ３−（５−アミノ−２−メチル−４−オキソ−４ｈ−キナゾリン−３−イル）−ピペリジン−２，６−ジオンを用いる癌の治療方法 |
| JP2018103019A Withdrawn JP2018168159A (ja) | 2011-03-11 | 2018-05-30 | ３−（５−アミノ−２−メチル−４−オキソ−４ｈ−キナゾリン−３−イル）−ピペリジン−２，６−ジオンを用いる癌の治療方法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013557916A Expired - Fee Related JP6118273B2 (ja) | 2011-03-11 | 2012-03-09 | 免疫関連疾患及び炎症性疾患の治療における３−（５−アミノ−２−メチル−４−オキソキナゾリン−３（４ｈ）−イル）ピペリジン−２，６−ジオンの使用 |
| JP2016248598A Pending JP2017081959A (ja) | 2011-03-11 | 2016-12-22 | 免疫関連疾患及び炎症性疾患の治療における３−（５−アミノ−２−メチル−４−オキソキナゾリン−３（４ｈ）−イル）ピペリジン−２，６−ジオンの使用 |
| JP2017009923A Expired - Fee Related JP6348192B2 (ja) | 2011-03-11 | 2017-01-24 | ３−（５−アミノ−２−メチル−４−オキソ−４ｈ−キナゾリン−３−イル）−ピペリジン−２，６−ジオンを用いる癌の治療方法 |
| JP2018103019A Withdrawn JP2018168159A (ja) | 2011-03-11 | 2018-05-30 | ３−（５−アミノ−２−メチル−４−オキソ−４ｈ−キナゾリン−３−イル）−ピペリジン−２，６−ジオンを用いる癌の治療方法 |
Country Status (29)
| Country | Link |
|---|---|
| US (6) | US20140148473A1 (enExample) |
| EP (3) | EP3025715A1 (enExample) |
| JP (5) | JP2014510078A (enExample) |
| KR (2) | KR20140025374A (enExample) |
| CN (3) | CN103561743A (enExample) |
| AR (1) | AR085651A1 (enExample) |
| AU (4) | AU2012229300B2 (enExample) |
| BR (2) | BR112013023277A2 (enExample) |
| CA (2) | CA2829592A1 (enExample) |
| CY (1) | CY1117430T1 (enExample) |
| DK (1) | DK2683384T3 (enExample) |
| EA (2) | EA201691939A1 (enExample) |
| ES (2) | ES2659205T3 (enExample) |
| HR (1) | HRP20160056T1 (enExample) |
| HU (1) | HUE027481T2 (enExample) |
| IL (2) | IL227990B (enExample) |
| MX (2) | MX2013010217A (enExample) |
| NI (2) | NI201300082A (enExample) |
| PH (2) | PH12013501820A1 (enExample) |
| PL (1) | PL2683384T3 (enExample) |
| PT (1) | PT2683384E (enExample) |
| RS (1) | RS54553B1 (enExample) |
| RU (3) | RU2013145524A (enExample) |
| SG (2) | SG193320A1 (enExample) |
| SI (1) | SI2683384T1 (enExample) |
| SM (1) | SMT201600034B (enExample) |
| TW (2) | TWI542349B (enExample) |
| WO (2) | WO2012125459A1 (enExample) |
| ZA (2) | ZA201306148B (enExample) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2066656E (pt) | 2006-09-26 | 2012-06-28 | Celgene Corp | Derivados de quinazolina substituídos em 5 como agentes antitumorais |
| WO2010137547A1 (ja) | 2009-05-25 | 2010-12-02 | 国立大学法人東京工業大学 | 中枢神経細胞の増殖及び分化に係る中核因子を含む医薬組成物 |
| CA3037184C (en) | 2011-03-11 | 2021-04-06 | Celgene Corporation | Solid forms of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses |
| WO2012135299A1 (en) | 2011-03-28 | 2012-10-04 | Deuteria Pharmaceuticals Inc | 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds |
| WO2012149299A2 (en) * | 2011-04-29 | 2012-11-01 | Celgene Corporaiton | Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor |
| CA2877736C (en) | 2012-06-29 | 2021-12-07 | Celgene Corporation | Methods for determining drug efficacy using cereblon-associated proteins |
| IL288506B2 (en) * | 2012-08-09 | 2023-09-01 | Celgene Corp | Methods for treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoisoindolin-2-yl)piperidine-2,6-dione |
| US9587281B2 (en) | 2012-08-14 | 2017-03-07 | Celgene Corporation | Cereblon isoforms and their use as biomarkers for therapeutic treatment |
| US9682952B2 (en) | 2012-09-04 | 2017-06-20 | Celgene Corporation | Isotopologues of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl) piperidine-2-6-dione and methods of preparation thereof |
| WO2014039960A1 (en) | 2012-09-10 | 2014-03-13 | Celgene Corporation | Methods for the treatment of locally advanced breast cancer |
| JP6359563B2 (ja) * | 2013-01-14 | 2018-07-18 | デュートルクス・リミテッド・ライアビリティ・カンパニーＤｅｕｔｅＲｘ， ＬＬＣ | ３−（５置換−４−オキソキナゾリン−３（４ｈ）−イル）−３−ジュウテロピペリジン−２，６−ジオン誘導体 |
| CA2941560A1 (en) | 2013-03-14 | 2014-09-25 | Deuterx, Llc | 3-(substituted-4-oxo-quinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives |
| HK1221174A1 (zh) * | 2013-04-17 | 2017-05-26 | 西格诺药品有限公司 | 用於治疗癌症的包括tor激酶抑制剂和5-取代喹唑啉酮化合物的组合疗法 |
| WO2014172432A1 (en) * | 2013-04-17 | 2014-10-23 | Signal Pharmaceuticals, Llc | Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer |
| CN105377831B (zh) * | 2013-05-01 | 2018-02-02 | 细胞基因公司 | 3‑(5‑氨基‑2‑甲基‑4‑氧代喹唑啉‑3(4h)‑基)哌啶‑2，6‑二酮的合成 |
| WO2014179661A1 (en) | 2013-05-03 | 2014-11-06 | Celgene Corporation | Methods for treating cancer using combination therapy |
| WO2015077058A2 (en) | 2013-11-08 | 2015-05-28 | The Broad Institute, Inc. | Compositions and methods for selecting a treatment for b-cell neoplasias |
| IL278381B2 (en) * | 2013-12-06 | 2024-08-01 | Celgene Corp | Methods for determining the effectiveness of a drug for the treatment of diffuse large B-cell lymphoma, multiple myeloma, and myeloid cancer |
| TW201540323A (zh) * | 2014-01-15 | 2015-11-01 | Celgene Corp | ３－（５－胺基－２－甲基－４－側氧基－４ｈ－喹唑啉－３－基）－哌啶－２，６－二酮之調配物 |
| WO2015200795A1 (en) | 2014-06-27 | 2015-12-30 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon other e3 ubiquitin ligases |
| MX2017000366A (es) * | 2014-07-11 | 2017-04-27 | Celgene Corp | Terapia de combinacion para el cancer. |
| EP3925609B1 (en) | 2014-08-22 | 2025-07-30 | Celgene Corporation | Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies |
| RU2017112748A (ru) * | 2014-11-17 | 2018-12-19 | Арно Терапьютикс, Инк. | Композиции онапристона пролонгированного действия и способы |
| TW201642857A (zh) * | 2015-04-06 | 2016-12-16 | 西建公司 | 以組合療法治療肝細胞癌 |
| BR112017028530A2 (pt) * | 2015-07-02 | 2018-08-28 | Celgene Corp | terapia combinada para tratamento de cânceres hematológicos e tumores sólidos |
| US9809603B1 (en) | 2015-08-18 | 2017-11-07 | Deuterx, Llc | Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same |
| ES2865289T3 (es) | 2015-08-27 | 2021-10-15 | Celgene Corp | Composiciones farmacéuticas que comprenden 3-(5-amino-2-metil-4-oxo-4H-quinazolin-3-il)-piperidin-2,6-diona |
| EP3347717A4 (en) | 2015-09-11 | 2019-06-05 | The Brigham and Women's Hospital, Inc. | PROCESS FOR CHARACTERIZING THE RESISTANCE TO CEREBLON MODULATORS |
| AU2016326657B2 (en) | 2015-09-25 | 2019-10-24 | Context Biopharma, Inc. | Methods of making onapristone intermediates |
| JP2018535992A (ja) | 2015-12-02 | 2018-12-06 | セルジーン コーポレイション | ３−（５−アミノ−２−メチル−４−オキソ−４ｈ−キナゾリン−３−イル）−ピペリジン−２，６−ジオンを使用するサイクリング療法 |
| KR20180113988A (ko) | 2015-12-15 | 2018-10-17 | 컨텍스트 바이오파마 인코포레이티드 | 비정질 오나프리스톤 조성물 및 그 제조방법 |
| WO2017117118A1 (en) | 2015-12-28 | 2017-07-06 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon and other e3 ubiquitin ligases |
| US11001566B2 (en) * | 2016-01-14 | 2021-05-11 | Kangpu Biopharmaceuticals, Ltd. | Quinazolinone derivative, preparation method therefor, pharmaceutical composition, and applications |
| EP3429996A4 (en) * | 2016-03-16 | 2020-02-12 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | SMALL MOLECULES AGAINST CEREBLON TO IMPROVE THE FUNCTION OF EFFECTOR T CELLS |
| WO2018102369A1 (en) | 2016-11-30 | 2018-06-07 | Arno Therapeutics, Inc. | Methods for onapristone synthesis dehydration and deprotection |
| US20180258064A1 (en) * | 2017-03-07 | 2018-09-13 | Celgene Corporation | Solid forms of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses |
| MY198676A (en) | 2017-06-22 | 2023-09-15 | Celgene Corp | Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection |
| WO2019077968A1 (en) | 2017-10-18 | 2019-04-25 | Canon Kabushiki Kaisha | PACKAGING CONTAINER AND PACKAGE |
| CN112313236A (zh) * | 2018-03-30 | 2021-02-02 | 拜欧斯瑞克斯公司 | 噻吩并嘧啶酮化合物 |
| SG11202012464WA (en) | 2018-07-11 | 2021-01-28 | H Lee Moffitt Cancer Center And Research Institute Inc | Dimeric immuno-modulatory compounds against cereblon-based mechanisms |
| EP3848371A4 (en) | 2018-09-07 | 2022-06-08 | Medshine Discovery Inc. | TRICYCLIC FURAN-SUBSTITUTED PIPERIDONEE COMPOUND |
| US11529339B2 (en) | 2018-10-01 | 2022-12-20 | Celgene Corporation | Combination therapy for the treatment of cancer |
| US12461103B2 (en) | 2019-03-22 | 2025-11-04 | University Of Ulsan Foundation For Industry Cooperation | Biomarker cereblon for diagnosing hepatocellular carcinoma, and novel monoclonal antibody specific thereto |
| US20230150978A1 (en) * | 2020-03-30 | 2023-05-18 | Enyo Pharma | Quinazolinone derivatives and uses thereof for treating a cancer |
| WO2024040036A2 (en) * | 2022-08-16 | 2024-02-22 | iTeos Belgium SA | Adenosine receptor antagonists and compositions thereof for use in the treatment of disease associated with expression of at least one antibody-secreting cell marker |
| CN118844365A (zh) * | 2024-06-26 | 2024-10-29 | 华南理工大学 | 一种化疗诱发的血液毒性斑马鱼模型及其应用 |
| CN119161336B (zh) * | 2024-07-24 | 2025-09-05 | 四川大学 | 一种作为Blimp1抑制剂的小分子化合物及其用途 |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| ES8702440A1 (es) | 1984-10-04 | 1986-12-16 | Monsanto Co | Un procedimiento para la preparacion de una composicion de polipeptido inyectable sustancialmente no acuosa. |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5391485A (en) | 1985-08-06 | 1995-02-21 | Immunex Corporation | DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues |
| US4810643A (en) | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
| JPS63500636A (ja) | 1985-08-23 | 1988-03-10 | 麒麟麦酒株式会社 | 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| PH30995A (en) | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| TW333456B (en) | 1992-12-07 | 1998-06-11 | Takeda Pharm Ind Co Ltd | A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide. |
| US5360352A (en) | 1992-12-24 | 1994-11-01 | The Whitaker Corporation | Wire retainer for current mode coupler |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US6087324A (en) | 1993-06-24 | 2000-07-11 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| EP0835101B1 (en) | 1995-06-27 | 2004-06-09 | Takeda Chemical Industries, Ltd. | Method of producing sustained-release preparation |
| TW448055B (en) | 1995-09-04 | 2001-08-01 | Takeda Chemical Industries Ltd | Method of production of sustained-release preparation |
| JP2909418B2 (ja) | 1995-09-18 | 1999-06-23 | 株式会社資生堂 | 薬物の遅延放出型マイクロスフイア |
| US5980945A (en) | 1996-01-16 | 1999-11-09 | Societe De Conseils De Recherches Et D'applications Scientifique S.A. | Sustained release drug formulations |
| US6264970B1 (en) | 1996-06-26 | 2001-07-24 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| US6419961B1 (en) | 1996-08-29 | 2002-07-16 | Takeda Chemical Industries, Ltd. | Sustained release microcapsules of a bioactive substance and a biodegradable polymer |
| CA2217134A1 (en) | 1996-10-09 | 1998-04-09 | Sumitomo Pharmaceuticals Co., Ltd. | Sustained release formulation |
| DK0839525T3 (da) | 1996-10-31 | 2004-11-29 | Takeda Pharmaceutical | Præparat med forlænget frigivelse |
| ZA9711385B (en) | 1996-12-20 | 1999-06-18 | Takeda Chemical Industries Ltd | Method of producing a sustained-release preparation |
| US5891474A (en) | 1997-01-29 | 1999-04-06 | Poli Industria Chimica, S.P.A. | Time-specific controlled release dosage formulations and method of preparing same |
| US6613358B2 (en) | 1998-03-18 | 2003-09-02 | Theodore W. Randolph | Sustained-release composition including amorphous polymer |
| KR19990085365A (ko) | 1998-05-16 | 1999-12-06 | 허영섭 | 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법 |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| AU1325102A (en) | 2000-10-16 | 2002-04-29 | Phylos Inc | Protein scaffolds for antibody mimics and other binding proteins |
| CZ20031855A3 (cs) * | 2000-12-06 | 2003-09-17 | Applied Research Systems Ars Holding N. V. | Použití SARP-1 pro léčbu a/nebo prevenci onemocnění sklerodermie |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| ATE472609T1 (de) | 2001-04-26 | 2010-07-15 | Amgen Mountain View Inc | Kombinatorische bibliotheken von monomerdomänen |
| US7498171B2 (en) | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
| US7393862B2 (en) | 2002-05-17 | 2008-07-01 | Celgene Corporation | Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias |
| US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| MX2007005884A (es) | 2004-11-16 | 2008-02-12 | Amgen Mountain View Inc | Andamios de proteina y usos de los mismos. |
| US20080051379A1 (en) | 2004-12-01 | 2008-02-28 | Trustees Of Boston University | Compositions and Methods for the Treatment of Peripheral B-Cell Neoplasms |
| PT2066656E (pt) * | 2006-09-26 | 2012-06-28 | Celgene Corp | Derivados de quinazolina substituídos em 5 como agentes antitumorais |
| GB0709092D0 (en) * | 2007-05-11 | 2007-06-20 | Borrebaeck Carl | Diagnosis and method of disease |
| CA2704710C (en) * | 2007-09-26 | 2016-02-02 | Celgene Corporation | 6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising the same |
| CA2707729A1 (en) * | 2007-12-07 | 2009-06-18 | Celgene Corporation | Biomarkers for monitoring the treatment by quinazolinone compounds |
| WO2010137547A1 (ja) | 2009-05-25 | 2010-12-02 | 国立大学法人東京工業大学 | 中枢神経細胞の増殖及び分化に係る中核因子を含む医薬組成物 |
| WO2012149299A2 (en) * | 2011-04-29 | 2012-11-01 | Celgene Corporaiton | Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor |
-
2012
- 2012-03-09 PL PL12710836T patent/PL2683384T3/pl unknown
- 2012-03-09 ES ES12710411.5T patent/ES2659205T3/es active Active
- 2012-03-09 DK DK12710836.3T patent/DK2683384T3/da active
- 2012-03-09 RS RS20160067A patent/RS54553B1/sr unknown
- 2012-03-09 JP JP2013557904A patent/JP2014510078A/ja not_active Withdrawn
- 2012-03-09 AU AU2012229300A patent/AU2012229300B2/en not_active Ceased
- 2012-03-09 BR BR112013023277A patent/BR112013023277A2/pt not_active IP Right Cessation
- 2012-03-09 MX MX2013010217A patent/MX2013010217A/es active IP Right Grant
- 2012-03-09 US US13/984,833 patent/US20140148473A1/en not_active Abandoned
- 2012-03-09 TW TW101108231A patent/TWI542349B/zh not_active IP Right Cessation
- 2012-03-09 HU HUE12710836A patent/HUE027481T2/en unknown
- 2012-03-09 ES ES12710836.3T patent/ES2562332T3/es active Active
- 2012-03-09 CA CA 2829592 patent/CA2829592A1/en not_active Abandoned
- 2012-03-09 PH PH1/2013/501820A patent/PH12013501820A1/en unknown
- 2012-03-09 CA CA 2829593 patent/CA2829593A1/en not_active Abandoned
- 2012-03-09 RU RU2013145524/15A patent/RU2013145524A/ru not_active Application Discontinuation
- 2012-03-09 MX MX2013010153A patent/MX2013010153A/es active IP Right Grant
- 2012-03-09 EP EP15197498.7A patent/EP3025715A1/en not_active Withdrawn
- 2012-03-09 SG SG2013066840A patent/SG193320A1/en unknown
- 2012-03-09 AR ARP120100782 patent/AR085651A1/es unknown
- 2012-03-09 SI SI201230451A patent/SI2683384T1/sl unknown
- 2012-03-09 EA EA201691939A patent/EA201691939A1/ru unknown
- 2012-03-09 WO PCT/US2012/028498 patent/WO2012125459A1/en not_active Ceased
- 2012-03-09 EP EP12710411.5A patent/EP2683383B1/en not_active Not-in-force
- 2012-03-09 KR KR20137026403A patent/KR20140025374A/ko not_active Ceased
- 2012-03-09 HR HRP20160056TT patent/HRP20160056T1/hr unknown
- 2012-03-09 AU AU2012229316A patent/AU2012229316B2/en not_active Ceased
- 2012-03-09 RU RU2013145556/15A patent/RU2013145556A/ru not_active Application Discontinuation
- 2012-03-09 TW TW105111258A patent/TW201700100A/zh unknown
- 2012-03-09 KR KR20137026402A patent/KR20140019364A/ko not_active Withdrawn
- 2012-03-09 RU RU2017120977A patent/RU2017120977A/ru not_active Application Discontinuation
- 2012-03-09 WO PCT/US2012/028538 patent/WO2012125475A1/en not_active Ceased
- 2012-03-09 EP EP12710836.3A patent/EP2683384B1/en active Active
- 2012-03-09 PH PH1/2013/501837A patent/PH12013501837A1/en unknown
- 2012-03-09 CN CN201280022744.2A patent/CN103561743A/zh active Pending
- 2012-03-09 SG SG2013064373A patent/SG192947A1/en unknown
- 2012-03-09 JP JP2013557916A patent/JP6118273B2/ja not_active Expired - Fee Related
- 2012-03-09 CN CN201280022778.1A patent/CN103561744A/zh active Pending
- 2012-03-09 BR BR112013023280A patent/BR112013023280A2/pt not_active IP Right Cessation
- 2012-03-09 US US13/417,088 patent/US8906932B2/en not_active Expired - Fee Related
- 2012-03-09 PT PT127108363T patent/PT2683384E/pt unknown
- 2012-03-09 EA EA201391319A patent/EA201391319A1/ru unknown
- 2012-03-09 CN CN201710232755.8A patent/CN107375293A/zh active Pending
-
2013
- 2013-08-15 ZA ZA2013/06148A patent/ZA201306148B/en unknown
- 2013-08-15 IL IL227990A patent/IL227990B/en active IP Right Grant
- 2013-08-21 ZA ZA2013/06305A patent/ZA201306305B/en unknown
- 2013-09-01 IL IL228230A patent/IL228230A/en not_active IP Right Cessation
- 2013-09-09 NI NI201300082A patent/NI201300082A/es unknown
- 2013-09-09 NI NI201300081A patent/NI201300081A/es unknown
-
2014
- 2014-11-05 US US14/533,941 patent/US20150126538A1/en not_active Abandoned
-
2016
- 2016-01-12 US US14/993,998 patent/US20160136167A1/en not_active Abandoned
- 2016-02-02 CY CY20161100088T patent/CY1117430T1/el unknown
- 2016-02-09 SM SM201600034T patent/SMT201600034B/xx unknown
- 2016-12-22 JP JP2016248598A patent/JP2017081959A/ja active Pending
-
2017
- 2017-01-24 JP JP2017009923A patent/JP6348192B2/ja not_active Expired - Fee Related
- 2017-02-22 US US15/439,879 patent/US20170165266A1/en not_active Abandoned
- 2017-04-11 US US15/484,850 patent/US20180055844A1/en not_active Abandoned
- 2017-06-28 AU AU2017204402A patent/AU2017204402A1/en not_active Abandoned
- 2017-08-04 AU AU2017210633A patent/AU2017210633A1/en not_active Abandoned
-
2018
- 2018-05-30 JP JP2018103019A patent/JP2018168159A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014510078A5 (enExample) | ||
| RU2013145524A (ru) | Способ лечения рака с использованием 3-(5-амино-2-метил-4-оксо-4н-хиназолин-3-ил)пиперидин-2, 6-диона | |
| Cordo' et al. | T-cell acute lymphoblastic leukemia: a roadmap to targeted therapies | |
| Iglesias et al. | Drug resistance in non-small cell lung cancer: a potential for NOTCH targeting? | |
| Dancsok et al. | Advances in sarcoma diagnostics and treatment | |
| Issa et al. | Epigenetic strategies to reverse drug resistance in heterogeneous multiple myeloma | |
| Díaz-Serrano et al. | Targeting EGFR in lung cancer: current standards and developments | |
| Riely et al. | EGFR: the paradigm of an oncogene-driven lung cancer | |
| Pérez-Galán et al. | Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era | |
| Brach et al. | EZH2 inhibition by tazemetostat results in altered dependency on B-cell activation signaling in DLBCL | |
| Iqbal et al. | Imatinib: a breakthrough of targeted therapy in cancer | |
| Easton et al. | mTOR and cancer therapy | |
| Tsai et al. | A multikinase and DNA-PK inhibitor combination immunomodulates melanomas, suppresses tumor progression, and enhances immunotherapies | |
| AU2018341571A1 (en) | Therapeutic methods relating to HSP90 inhibitors | |
| MX2013012564A (es) | Metodos para el tratamiento del cancer y enfermedades inflamatorias utilizando cereblon como predictor. | |
| CA2850175C (en) | Biomarkers for predicting sensitivity to cancer treatments | |
| JP2021098750A (ja) | がんを治療するためのｍｄｍ２阻害剤の投与計画 | |
| WO2016170163A1 (en) | Substituted quinoxalines and benzotriazine p70s6 kinase inhibitors | |
| WO2021138215A1 (en) | Treatment of cancer with cdk12/13 inhibitors | |
| Frett et al. | Therapeutic Melting Pot of Never in Mitosis Gene A Related Kinase 2 (Nek2): A Perspective on Nek2 as an Oncology Target and Recent Advancements in Nek2 Small Molecule Inhibition: Miniperspective | |
| EP3484477B1 (en) | Treatment of cancer | |
| KR20080004495A (ko) | 암을 치료하기 위한 조합물, 방법 및 조성물 | |
| EP3356348A1 (en) | 2-aminoquinazoline derivatives as p70s6 kinase inhibitors | |
| Ryspayeva et al. | Signaling pathway dysregulation in breast cancer | |
| Quintás‐Cardama et al. | Advances and controversies in the diagnosis, pathogenesis, and treatment of systemic mastocytosis |